Allarity Therapeutics Sees FY2026 GAAP EPS $(0.76)-$(0.73) vs $(0.80) Est

Benzinga · 1d ago
Allarity Therapeutics (NASDAQ:ALLR) is looking for FY2026 GAAP EPS of $(0.76)-$(0.73) vs $(0.80) analyst estimate..